News

Fierce Biotech8h
With $550M on the line, Arrowhead reassures investors about pact with troubled Sarepta
Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaboration Agreement with Sarepta Therapeutics.
Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns
We recently published 10 Big Names Get Slammed. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the biggest losers on ...
Arrowhead Pharma Shares Rise After Statement on Sarepta Deal
Shares of Cambridge, Mass.-based Sarepta have fallen by more than 90% in the last year amid safety concerns about its Elevidys, a gene therapy that treats Duchenne muscular dystrophy, following ...
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.
BioSpace18h
Zhen Li: A Reluctant Engineer Shaping the World of siRNA
ADARx Pharmaceuticals CEO Zhen Li found her way to biopharma through Merck, where she was inspired by the application of ...
The Motley Fool2y
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (ARWR-11.09%) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 ...